rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
7
|
pubmed:dateCreated |
2003-7-11
|
pubmed:abstractText |
To characterize the activities of irofulven, a novelanticancer agent derived from the mushroom natural productilludin S toward human cancer cells. Experimental Design: We have determined the activity spectrum of irofulven toward a human tumor cell panel comprised of 10 different tumor types in comparison with cisplatin and ET-743. We have also evaluated the influence of major resistance mechanisms, such as expression of multidrug resistance-associated drug efflux pumps, cisplatin resistance, loss of p53 function, and absence of mismatch repair on the cytotoxic activity of irofulven.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Alkylating,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Culture Media,
http://linkedlifedata.com/resource/pubmed/chemical/Dioxoles,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamate-Cysteine Ligase,
http://linkedlifedata.com/resource/pubmed/chemical/Glutathione Transferase,
http://linkedlifedata.com/resource/pubmed/chemical/Isoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Plant Extracts,
http://linkedlifedata.com/resource/pubmed/chemical/Sesquiterpenes,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrahydroisoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/illudin S,
http://linkedlifedata.com/resource/pubmed/chemical/irofulven,
http://linkedlifedata.com/resource/pubmed/chemical/rho GTP-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/trabectedin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1078-0432
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
9
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2817-25
|
pubmed:dateRevised |
2008-11-29
|
pubmed:meshHeading |
pubmed-meshheading:12855662-Antibiotics, Antineoplastic,
pubmed-meshheading:12855662-Antineoplastic Agents, Alkylating,
pubmed-meshheading:12855662-Blotting, Western,
pubmed-meshheading:12855662-Carcinoma,
pubmed-meshheading:12855662-Cell Line, Tumor,
pubmed-meshheading:12855662-Cisplatin,
pubmed-meshheading:12855662-Culture Media,
pubmed-meshheading:12855662-Dioxoles,
pubmed-meshheading:12855662-Drug Resistance, Neoplasm,
pubmed-meshheading:12855662-Epithelial Cells,
pubmed-meshheading:12855662-Glutamate-Cysteine Ligase,
pubmed-meshheading:12855662-Glutathione Transferase,
pubmed-meshheading:12855662-Humans,
pubmed-meshheading:12855662-Isoquinolines,
pubmed-meshheading:12855662-Models, Chemical,
pubmed-meshheading:12855662-P-Glycoprotein,
pubmed-meshheading:12855662-Plant Extracts,
pubmed-meshheading:12855662-Sesquiterpenes,
pubmed-meshheading:12855662-Tetrahydroisoquinolines,
pubmed-meshheading:12855662-Time Factors,
pubmed-meshheading:12855662-Tumor Suppressor Protein p53,
pubmed-meshheading:12855662-rho GTP-Binding Proteins
|
pubmed:year |
2003
|
pubmed:articleTitle |
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
|
pubmed:affiliation |
Laboratory of Biology and Pharmacogenetics of Human Tumors, Centre National de la Recherche Scientifique Unité Mixte de Recherche, Ecole Normale Supérieure, Cachan and Institut Gustave-Roussy, Villejuif 94805 cedex, France.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|